Basis: Current FMP quote-based enterprise value / four-quarter operating income. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/EBIT ratio is N/A as of 2026-10-06T14:06:08.591Z.
Calculation as of: 2026-10-06T14:06:08.591Z.
Quote observation: 2026-10-06T14:05:04.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: f12fe6f09ebba39ad61e3a87243b01e46bba3d7bd48a90cbad4cda1dbeff8bd9
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/EBIT RATIO
N/A
Market Cap
$51.72M
EV/EBIT Ratio
N/A
TTM Avg
36.45x
3Y Avg
39.02x
5Y Avg
39.02x
Market Cap
$45.60M
EV/EBIT Ratio
N/A
TTM Avg
7.97x
3Y Avg
11.01x
5Y Avg
11.01x
| NAME | MARKET CAP | EV/EBIT RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Clene Inc. (CLNN) | $49.00M | N/A | N/A | N/A | N/A |
| Celularity Inc. (CELU)vs › | $48.03M | N/A | N/A | N/A | N/A |
| Lite Strategy, Inc. (LITS)vs › | $47.47M | N/A | N/A | N/A | N/A |
| Envoy Medical, Inc. (COCH)vs › | $50.95M | N/A | N/A | N/A | N/A |
| INmune Bio, Inc. (INMB)vs › | $51.28M | N/A | N/A | N/A | N/A |
| eXoZymes, Inc. (EXOZ)vs › | $51.51M | N/A | N/A | N/A | N/A |
| biote Corp. (BTMD)vs › | $51.61M | 11.46x | 6.17x | 6.96x | 6.04x |
| Microbot Medical Inc. (MBOT)vs › | $51.72M | N/A | 36.45x | 39.02x | 39.02x |
| BioStem Technologies, Inc. (BSEM)vs › | $45.60M | N/A | 7.97x | 11.01x | 11.01x |
| DarioHealth Corp. (DRIO)vs › | $45.37M | N/A | 17.26x | 19.56x | 25.78x |
EV/EBIT = Enterprise Value / EBIT (TTM)
Enterprise value to EBIT compares total company value to operating earnings, accounting for depreciation unlike EV/EBITDA.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
